Marco is a General Partner at Forbion and joined the team in 2007.
Marco is a General Partner at Forbion and has been a part of the team since 2007. Before joining Forbion, Marco was Business Development Director at DSM Pharmaceutical Products, managing biomanufacturing technologies and contract manufacturing projects, and developed manufacturing processes for biosimilars at Cytos Biotechnology.
He is especially interested in applying his experience with both small and large businesses in the fields of biotechnology, operations, and business development to the Forbion portfolio, with particular emphasis on establishing and managing new companies as part of Forbion’s build strategy.
Marco was the founding CEO of VectorY Therapeutics and was also instrumental in the launch of several biotechs, including NorthSea Therapeutics, Oxitope Pharma, Sidera, and Dezima Pharma (acquired by Amgen for up to USD 1.5 billion). He currently serves on the boards of Calluna Pharma, Orbis Medicines, Purespring Therapeutics, Rectify Pharma, Sidera Bio, Sitala, and VectorY Therapeutics.
Marco also served on the boards of Akarna (acquired by Allergan for up to USD 1 billion), Prexton Therapeutics (acquired by Lundbeck for up to USD 1.1 billion), Inflazome (acquired by Roche for USD 450 million plus contingent milestone payments), and Inversago (acquired by Novo Nordisk for up to USD 1.1 billion). Additionally, he has been a board member of Nasdaq-listed companies enGene ($ENGN), Milestone Pharmaceuticals ($MIST), and Replimune ($REPL).
Marco has an MSc in Molecular Biology from the University of Groningen and holds a PhD in Biotechnology from the ETH Institute for Technology in Zürich, Switzerland.
My favored ingredients to produce an extraordinary and successful innovative business? Optimal dosing of talent, entrepreneurship, and hard work.
Portfolio
Companies worked on by Marco Boorsma
